跳至主要内容
临床试验/NL-OMON51652
NL-OMON51652招募中不适用

Predicting Response In Cervical intraepithelial neoplasia to Topical Imiquimod treatment (PRedICT-TOPIC) - PRedICT-TOPIC

Catharina-ziekenhuis0 个研究点目标入组 410 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
410

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Primary cHSIL lesions (e.g. CIN3 or CIN 2), histologically confirmed by
  • diagnostic biopsy
  • NB: In case of CIN 2, <30 years, expectative management must be discussed
  • according to the Dutch national guideline with the patient, if the patient
  • prefers imiquimod therapy the patient can be treated with imiquimod and
  • enrolled in the study, if the patient prefers expectative management they can
  • be enrolled in the observational CIN 2 arm.
  • - Recurrent or residual cHSIL lesions after initial LLETZ treatment (e.g. CIN2
  • or CIN3), histologically confirmed by diagnostic biopsy
  • - Age of 18 years or older

排除标准

  • - Concomitant diagnoses of VAIN (vaginal intraepithelial neoplasia e.g. vaginal
  • - PAP 4 cytology as indication for the baseline colposcopy at study entrance
  • - Adenocarcinoma in situ (AIS) diagnosis
  • - Previous imiquimod therapy for cHSIL
  • - previous cervical malignancy
  • - current malignant disease
  • - immunodeficiency (including HIV/AIDS and immunosuppressive medication)
  • - pregnancy
  • - legal incapability
  • - insufficient knowledge of the Dutch language

研究者

相似试验